Ligand ID: 08Y Drugbank ID: DB01200(Bromocriptine) Indication:For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | PHE D 3SER B 284THR D 111ALA D 285THR D 280 | 1.66A | 21.27 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | PHE D 3SER B 284THR D 111ALA D 285THR D 280 | 1.53A | 21.06 | None | ||
![]() | 5VCG_A_08YA602_2 (CYTOCHROME P450 3A4) | 6m3m | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 3 / 3 | ARG B 90ARG B 89ARG B 93 | 0.91A | 14.29 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 100PHE A 219ILE A 86PHE A 192ALA A 195 | 1.78A | 19.33 | None | ||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 623ILE A 757PHE A 694THR A 680ALA A 702 | 1.71A | 19.22 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 623ILE A 757PHE A 694THR A 680ALA A 702 | 1.68A | 19.33 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 126PHE A 134THR A 141PHE A 165THR A 462 | 1.61A | 19.33 | None | ||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ARG A 631SER A 635ILE A 632THR A 701ALA A 639 | 1.78A | 19.22 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE C 888SER C 816ILE C 818ALA C 871ALA C 876 | 1.26A | 17.68 | None | ||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE C 888SER C 816ILE C 818ALA C 871ALA C 876 | 1.28A | 17.29 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6vww | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | SER A 98ILE A 108THR A 49ALA A 55GLU A 57 | 1.38A | 22.47 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A1121ILE B 923THR A1077ALA A1080GLU B 918 | 1.50A | 17.43 | None | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 6 / 12 | PHE A1121PHE B 906ILE B 923ALA B 899ALA A1080GLU B 918 | 1.67A | 17.59 | None | ||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A1052ARG A 905ILE C 712ALA C 706ALA A 879 | 1.57A | 17.28 | NoneNoneNoneNAG C1315 (-3.4A)None | ||
![]() | 5VCG_A_08YA602_2 (CYTOCHROME P450 3A4) | 6vyo | NUCLEOPROTEIN (SARS-CoV-2) | 3 / 3 | ARG D 89ARG D 88ARG D 92 | 0.88A | 13.91 | NoneNoneMES A 201 ( 4.0A) | ||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w4h | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.65A | 20.97 | ACT A7104 (-4.7A)NoneNoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP A6912PHE A6954PHE A6868THR A6915ALA A6966 | 1.70A | SAM A7104 (-3.6A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP A6912ILE A6955PHE A6868THR A6915ALA A6966 | 1.59A | SAM A7104 (-3.6A)NoneNoneNoneNone | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.63A | EDO A7102 (-4.8A)KCX A6935 ( 3.6A)NoneNoneNone | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.59A | 14.79 | NoneFMT A7103 ( 4.4A)NoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ASP C6912ILE C6955PHE C6868THR C6915ALA C6966 | 1.60A | 14.79 | SAM C7105 ( 3.5A)NoneNoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.66A | 14.79 | NoneFMT A7103 ( 4.4A)NoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ASP A6912PHE A6954PHE A6868THR A6915ALA A6966 | 1.71A | 14.79 | SAM A7102 ( 3.5A)NoneNoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ASP C6912PHE C6954PHE C6868THR C6915ALA C6966 | 1.71A | 14.79 | SAM C7105 ( 3.5A)NoneNoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ASP A6912ILE A6955PHE A6868THR A6915ALA A6966 | 1.61A | 14.79 | SAM A7102 ( 3.5A)NoneNoneNoneNone | ||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE C 241PHE C 147ALA C 139THR C 102GLU C 124 | 1.78A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ARG C 138PHE C 147ALA C 144THR C 102ALA C 141 | 1.52A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ARG C 166SER C 245PHE C 173PHE C 304THR C 115 | 1.63A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE A 127PHE A 147ALA A 139THR A 102GLU A 124 | 1.56A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE C 304PHE C 127PHE C 147ALA C 139THR C 102 | 1.49A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE B 304PHE B 127PHE B 147ALA B 139THR B 102 | 1.55A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE C 127PHE C 147ALA C 139THR C 102GLU C 124 | 1.58A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ARG A 166SER A 245PHE A 173PHE A 304THR A 115 | 1.67A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE B 127PHE B 147ALA B 139THR B 102GLU B 124 | 1.57A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ARG B 138PHE B 147ALA B 144THR B 102ALA B 141 | 1.45A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ARG B 166SER B 245PHE B 173PHE B 304THR B 115 | 1.54A | NoneNoneNoneNone CL B 502 ( 4.9A) | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE A 304PHE A 127PHE A 147ALA A 139THR A 102 | 1.42A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE B 92ILE A 68ALA A 65ALA B 81GLU A 74 | 1.79A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 314PHE B 315ILE A 304PHE B 314ALA A 313 | 1.79A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | PHE B 314PHE A 315ILE B 304PHE A 314ALA B 313 | 1.79A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | PHE C 314PHE D 315ILE C 304PHE D 314ALA C 313 | 1.78A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | PHE D 314PHE C 315ILE D 304PHE C 314ALA D 313 | 1.77A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP A6912ILE A6955PHE A6868THR A6915ALA A6966 | 1.62A | SAH A7102 (-3.5A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP C6912PHE C6954PHE C6868THR C6915ALA C6966 | 1.72A | SAH C7102 (-3.3A)NoneNoneFMT C7107 (-3.7A)None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP A6912PHE A6954PHE A6868THR A6915ALA A6966 | 1.72A | SAH A7102 (-3.5A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE C6948THR C6934ALA C6808THR C6989ALA C6966 | 1.65A | NoneFMT C7104 (-4.2A)NoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP C6912ILE C6955PHE C6868THR C6915ALA C6966 | 1.61A | SAH C7102 (-3.3A)NoneNoneFMT C7107 (-3.7A)None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE C6948THR C6934ALA C6808THR C6989ALA C6966 | 1.59A | NoneFMT C7104 (-4.2A)NoneNoneNone | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.62A | NoneFMT A7103 (-4.6A)NoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.70A | NoneFMT A7103 (-4.6A)NoneNoneNone | |||
![]() | 5VCG_A_08YA602_2 (CYTOCHROME P450 3A4) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 3 / 3 | ARG C 89ARG C 88ARG C 107 | 1.60A | 13.32 | NoneNoneMES D 201 (-4.5A) | ||
![]() | 5VCG_A_08YA602_2 (CYTOCHROME P450 3A4) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 3 / 3 | ARG B 89ARG B 88ARG B 107 | 1.43A | 13.32 | None | ||
![]() | 5VCG_A_08YA602_2 (CYTOCHROME P450 3A4) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 3 / 3 | ARG D 89ARG D 88ARG D 107 | 1.47A | 13.32 | None | ||
![]() | 5VCG_A_08YA602_2 (CYTOCHROME P450 3A4) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 3 / 3 | ARG A 89ARG A 88ARG A 107 | 1.51A | 13.32 | NoneNoneMES B 201 (-4.8A) | ||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6948THR C6934ALA C6808THR C6989ALA C6966 | 1.65A | FMT C7105 ( 4.4A)FMT C7104 ( 4.7A)NoneNoneNone | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.61A | NoneFMT A7105 ( 4.6A)NoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.68A | NoneFMT A7105 ( 4.6A)NoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ASP A6912ILE A6955PHE A6868THR A6915ALA A6966 | 1.62A | SFG A7103 ( 3.3A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ASP A6912PHE A6954PHE A6868THR A6915ALA A6966 | 1.73A | SFG A7103 ( 3.3A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ASP C6912ILE C6955PHE C6868THR C6915ALA C6966 | 1.61A | SFG C7103 ( 3.4A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ASP C6912PHE C6954PHE C6868THR C6915ALA C6966 | 1.73A | SFG C7103 ( 3.4A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6948THR C6934ALA C6808THR C6989ALA C6966 | 1.73A | FMT C7105 ( 4.4A)FMT C7104 ( 4.7A)NoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | SER B 98ILE B 108THR B 49ALA B 55GLU B 57 | 1.40A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | PHE B 123ILE B 144THR B 99ALA B 161THR B 167 | 1.69A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | SER A 98ILE A 108THR A 49ALA A 55GLU A 57 | 1.41A | NoneNoneNoneNoneEDO A 403 (-3.6A) | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | PHE A 123ILE A 144THR A 99ALA A 161THR A 167 | 1.70A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP A6912PHE A6954PHE A6868THR A6915ALA A6966 | 1.72A | SAH A7101 (-3.3A)NoneNoneNoneNone | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6948THR A6934ALA A6808THR A6989ALA A6966 | 1.61A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASP A6912ILE A6955PHE A6868THR A6915ALA A6966 | 1.62A | SAH A7101 (-3.3A)NoneNoneNoneNone | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | PHE A 304PHE A 127PHE A 147ALA A 139THR A 102 | 1.62A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | ARG A 140THR A 277PHE A 147ALA A 135ALA A 141 | 1.75A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 6yi3 | NUCLEOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 131ASP A 23ARG A 49ALA A 10ALA A 15 | 1.79A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 126PHE A 134THR A 141PHE A 165THR A 462 | 1.57A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 100PHE A 219ILE A 86PHE A 192ALA A 195 | 1.77A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 441ASP A 845ARG A 836SER A 814ALA A 550 | 1.78A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 454ARG A 457ILE A 171ALA A 176THR A 252 | 1.73A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 623ILE A 757PHE A 694THR A 680ALA A 702 | 1.75A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 211THR A 120ALA A 176THR A 252ALA A 250 | 1.78A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ARG A 631SER A 635ILE A 632THR A 701ALA A 639 | 1.78A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 684ILE A 696THR A 680THR A 591ALA A 580 | 1.59A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 684ILE A 696THR A 680THR A 591ALA A 580 | 1.64A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 126PHE A 134THR A 141PHE A 165THR A 462 | 1.61A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 454ARG A 457ILE A 171ALA A 176THR A 252 | 1.73A | None | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 684ILE A 696THR A 680THR A 591ALA A 580 | 1.51A | NoneNoneF86 P 102 ( 4.9A)None A T 13 ( 3.7A) | |||
![]() | 3UA1_A_08YA600_1 (CYTOCHROME P450 3A4) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 454ARG A 457ILE A 171ALA A 176THR A 252 | 1.68A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 684ILE A 696THR A 680THR A 591ALA A 580 | 1.53A | NoneNoneF86 P 102 ( 4.9A)None A T 13 ( 3.7A) | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 321PHE A 313ILE A 466PHE A 317THR A 248 | 1.45A | None | |||
![]() | 5VCG_A_08YA602_1 (CYTOCHROME P450 3A4) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 126PHE A 134THR A 141PHE A 165THR A 462 | 1.59A | None |